Biohaven Enrolls 1st Patient in Phase 2/3 Trial of Trigriluzole for Mild to Moderate Alzheimer’s

Biohaven Enrolls 1st Patient in Phase 2/3 Trial of Trigriluzole for Mild to Moderate Alzheimer’s
Biohaven Pharmaceuticals has enrolled the first patient in its Phase 2/3 clinical trial investigating the potential of trigriluzole as a treatment for patients with mild to moderate Alzheimer's disease. The study, which is currently recruiting, is being conducted in collaboration with the Alzheimer's Disease Cooperative Study (ADCS) at four clinical sites in the U.S. Trigriluzole, also known as BHV-4157, is a new compound precursor of
Subscribe or to access all post and page content.